We could not find any results for:
Make sure your spelling is correct or try broadening your search.
IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced today a...
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell therapies, presented in an oral session...
- Presented new preclinical data demonstrating proof-of-concept for non-signaling Chimeric Antigen Receptor (nsCAR) platform to effectively target cancer cells while preserving healthy tissue...
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell therapies, announced today that the...
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an oral...
NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that...
- Preclinical data supports potential for proprietary nsCAR platform to selectively eliminate cancer cells while preserving healthy tissue - Gamma-delta nsCAR platform emerging as an advanced...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.03 | 3 | 1 | 1.16 | 0.9837 | 250094 | 1.08953797 | CS |
4 | 0.01 | 0.980392156863 | 1.02 | 1.16 | 0.94 | 153393 | 1.05030663 | CS |
12 | 0.01 | 0.980392156863 | 1.02 | 1.45 | 0.9164 | 349915 | 1.11079403 | CS |
26 | 0.12 | 13.1868131868 | 0.91 | 2.48 | 0.65 | 501730 | 1.38399221 | CS |
52 | -1.66 | -61.7100371747 | 2.69 | 3.48 | 0.65 | 327933 | 1.49783758 | CS |
156 | -8.97 | -89.7 | 10 | 10.319 | 0.65 | 587652 | 2.52633975 | CS |
260 | -8.97 | -89.7 | 10 | 10.319 | 0.65 | 587652 | 2.52633975 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions